Autoimmune Myasthenia Gravis (MG) is rarely reported from low-resource settings, where diagnostic delays and limited therapeutic options remain major challenges. We report a young adult with progressive, fluctuating muscle weakness evolving over three years before diagnosis. In the absence of antibody testing and thoracic imaging, the diagnosis relied on clinical features and electrophysiological confirmation through a reproducible decrement on repetitive nerve stimulation. Corticosteroid therapy resulted in significant clinical improvement despite limited access to pyridostigmine and immunosuppressive agents. This report emphasizes the feasibility of diagnosing and managing myasthenia gravis based primarily on clinical expertise and electrophysiological testing in resource-constrained environments, and underscores the need for strengthened diagnostic capacity and access to essential medications.
Cite this paper
Soumah, C. O. , Diallo, M. T. , Touré, M. L. , Barry, S. D. and Cissé, F. A. (2026). Young-Onset Autoimmune Myasthenia Gravis in a Resource-Limited Setting: A Clinical Case Report. Open Access Library Journal, 13, e14130. doi: http://dx.doi.org/10.4236/oalib.1114130.
Grob, D., Brunner, N., Namba, T. and Pagala, M. (2008) Lifetime Course of Myasthenia Gravis. Muscle & Nerve, 37, 141-149. https://doi.org/10.1002/mus.20950
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A. and Vincent, A. (2001) Auto-Antibodies to the Receptor Tyrosine Kinase Musk in Patients with Myasthenia Gravis without Acetylcholine Receptor Antibodies. Nature Medicine, 7, 365-368. https://doi.org/10.1038/85520
Sanders, D.B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., et al. (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 96, 114-122. https://doi.org/10.1212/wnl.0000000000011124
Howard Jr., J.F., Barohn, R.J., Cutter, G.R., et al. (2017) Eculizumab in Refractory Generalized Myasthenia Gravis. The New England Journal of Medicine, 377, 631-639.
Howard Jr., J.F., Bril, V., Vu, T., et al. (2022) Safety and Efficacy of Ravulizumab in Adults with Generalized Myasthenia Gravis: The Champion-Mg Trial. The Lancet Neurology, 21, 589-600.
Marx, A., Müller‐Hermelink, H.K. and Ströbel, P. (2003) The Role of Thymomas in the Development of Myasthenia Gravis. Annals of the New York Academy of Sciences, 998, 223-236. https://doi.org/10.1196/annals.1254.025
Mantegazza, R. and An-tozzi, C. (2018) When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies. Therapeutic Advances in Neurological Disorders, 11, Article 1756285617749134.
Kouassi, B., Napon, C., Kaboré, J., Millogo, A., Assogba, K., et al. (2018) Difficultés diagnostiques de la myasthénie dans les pays à ressources limitées: Expérience ouest-africaine. Revue Neurologique (Paris), 174, 577-582.